Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2025-03-07 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 07.03.2025 from Medicamen Biotech Limited addressed to stock exchanges. It discloses a new business understanding with a South African conglomerate for product registration and marketing, highlighting strategic expansion and recent EU approval. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is a brief business update without financial statements or detailed financial data. The document length is 1552 characters, which is short and does not contain a full report or financial results. It is an announcement of a business development rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2025-03-07 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (920 characters) and consists solely of digital signature blocks with no substantive content, financial data, or report information. There are no references to any report titles, fiscal periods, or regulatory bodies. The content does not contain any financial statements, management commentary, or announcements. Given the lack of meaningful content and the presence of only digital signatures, this document does not represent a financial report or announcement but rather appears to be a certification or attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2025-03-05 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the publication of a newspaper notice regarding the dispatch of the Notice of an Extra-Ordinary General Meeting (EGM) and remote e-voting details. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure and publication requirements. The document does not contain any financial data, detailed meeting materials, voting results, or management information. It is essentially an announcement about the publication of a notice for an EGM, not the notice itself or any voting results. Given the short length (1299 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-04 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice of an Extraordinary General Meeting (EGM) scheduled for March 26, 2025, including the agenda for the meeting which is the issuance of equity shares on a preferential basis. It includes procedural details such as voting dates, cut-off dates, regulatory references (SEBI Listing Regulations, SEBI ICDR Regulations, Companies Act 2013), and instructions for remote e-voting. The document is not a report of financial results or an announcement of results but a formal meeting notice with resolutions to be considered by shareholders. It is not a proxy solicitation or voting results declaration but the actual meeting notice. The length and content confirm it is the EGM Notice itself, which falls under the category of Proxy Solicitation & Information Statement (PSI) as it is sent to shareholders to provide information and request votes for the meeting. Therefore, the correct classification is PSI.
2025-03-03 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement informing stock exchanges about an award received by the company Medicamen Biotech Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to material events or information disclosures. There is no financial data, no report attached or referenced, and no mention of financial results, management changes, or other report types. The document is an informational regulatory announcement about a corporate recognition event, fitting best under general regulatory announcements.
2025-02-27 English
Issue of Securities
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board of Directors meeting held on February 26, 2025. The content focuses on the approval of a preferential issue of equity shares and fully convertible warrants, including details of the proposed allottees, issue price, and regulatory compliance references (SEBI ICDR Regulations, SEBI Listing Regulations). It also mentions the constitution of a Preferential Issue Committee and approval of a draft notice for an Extraordinary General Meeting to seek member approval. The document includes detailed annexures with disclosures required under SEBI circulars. This is a regulatory announcement about capital raising activities and board decisions, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the capital issue. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-02-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.